Three new manufacturing contracts with Materia Medica Holding
The Edinburgh-based contract manufacturer said the latest contract wins will run concurrently to existing contracts and will take around 22-months to complete.
Angel agreed a joint venture with MMH last October to make new drugs, which included the setting up of a dedicated manufacturing unit on behalf of MMH.
The new unit is based at the Cramlington facility in Northumberland which Angel is currently re-commissioning.
Angel also announced last December it had entered into a framework agreement with US-based TransGenRx to manage development and production of a protein product for the Lousiana based firm.
Under the current agreements with MMH, Angel will carry on within its existing facilities near Penicuik with a view to transferring production to its Cramlington site later this year.
MMH intends to have at least seven products made in the first few years with the agreement being reviewed after five years.
Dr Paul Harper, executive chairman of Angel Biotechnology Holdings, said: "The commission of these three new agreements provides a robust basis for the proposed JVC (joint venture company) between Angel and MMH and demonstrates the confidence the customer has in Angel's capabilities.
"These agreements will put the proposed JVC on a sure footing from the outset, but is also an excellent example of the value Angel can provide via significant alliances such as this. I would like to thank MMH for making this commercial commitment."
Professor Oleg Epstein, general director of MMH, added: "By signing these three new agreements with Angel, MMH can act in a timely manner to bring these products to market.
"As core business, it is important tous that development work begins whilst the JVC is being established.I am positive this will provide the best possible start to the new JVC."